Evaluation of the effect of melatonin on COVID 19

Phase 3

Conditions: covid 19.
covid 19
U07.0

Registration Number: IRCT20210411050925N1

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 100

Inclusion Criteria

Patients with positive RT-PCR for COVID19
Ability to sign consent and sufficient literacy
No history of melatonin use during the study
Admission in ICU
Age over 20 years

Exclusion Criteria

Other systemic diseases (such as uncontrollable hypertension, uncontrolled diabetes, depression, elevated liver enzymes more than 3 times normal, cirrhosis, chronic kidney disease with GFR less than 30 cc / min)
Allergy to melatonin
Usage of anticoagulants such as warfarin or heparin with therapeutic doses
Under mechanical ventilation

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The inflammatory factors level. Timepoint: At the beginning of the study and 5 day after starting the drug/placebo. Method of measurement: Evaluation of blood levels of inflammatory factors.;Total duration of hospitalization and ICU residency. Timepoint: Determination of hospitalization date,admission to ICU,discharge from ICU,discharge from hospital. Method of measurement: Reading the files.;Oxygenation level. Timepoint: Daily assessment of oxygenation from admission time till discharge. Method of measurement: Pulse oxymetry.

Secondary Outcome Measures

Name	Time	Method
Measurement of CRP level as inflammatory marker. Timepoint: At the beginning of the study and day 5 after starting the drug/placebo. Method of measurement: Serum level measurement.;Measurement of ESR level as inflammatory marker. Timepoint: At the beginning of the study and day 5 after starting the drug/placebo. Method of measurement: Serum level measurement.;Measurement of LDH level as inflammatory marker. Timepoint: At the beginning of the study and day 5 after starting the drug/placebo. Method of measurement: Serum level measurement.